$0.05
(Market cap
$400 Mln
Recently Viewed
Clear AllMarket cap
$400 Mln
Revenue (TTM)
$1,225 Mln
P/E Ratio
5.1
P/B Ratio
0.6
Div. Yield
0 %
Value Research Rating
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$365 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.8
Debt to Equity
0
Book Value
$--
EPS
$3.1
Face value
--
Shares outstanding
133,915,000
CFO
CN¥6,407.34 Mln
EBITDA
CN¥3,970.72 Mln
Net Profit
CN¥2,577.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Global Cord Blood - ADR
| -62.2 | -0.9 | -62.2 | -56.5 | -30.6 | -32.7 | -10.3 |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Global Cord Blood - ADR
| -28.6 | 12.9 | -25.8 | -22.5 | -34.4 | 62.6 | -3.9 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction... of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd. Read more
CEO & CEO of Beijing Division
Ms. Ting Zheng
Chief Financial Officer
Mr. Bing Chuen Chen
Headquarters
Central
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Global Cord Blood Corporation - ADR is $1.13 (NYSE) as of 12-Jul-2023 09:30 EDT. Global Cord Blood Corporation - ADR has given a return of -30.6% in the last 3 years.
The P/E ratio of Global Cord Blood Corporation - ADR is 5.06 times as on 19-May-2023.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
0.94
|
0.10
|
|
2021
|
1.08
|
0.13
|
|
2020
|
0.82
|
0.10
|
|
2019
|
2.97
|
0.25
|
|
2018
|
5.25
|
0.40
|
The 52-week high and low of Global Cord Blood Corporation - ADR are Rs -- and Rs -- as of 11-Apr-2026.
Global Cord Blood Corporation - ADR has a market capitalisation of $ 400 Mln as on 19-May-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Global Cord Blood Corporation - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.